VANDRIA
Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders.
VANDRIA
Social Links:
Industry:
Manufacturing Pharmaceutical
Founded:
2021-01-01
Address:
Lausanne, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.vandria.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
21.5 M CHF
Technology used in webpage:
Amazon Smart App Banner Nextcloud
Investors List
Eurostars
Eurostars investment in Grant - Vandria
Innosuisse
Innosuisse investment in Grant - Vandria
+ND Capital
+ND Capital investment in Series A - Vandria
Official Site Inspections
http://www.vandria.com Semrush global rank: 7 M Semrush visits lastest month: 945
- Host name: ec2-54-194-41-141.eu-west-1.compute.amazonaws.com
- IP address: 54.194.41.141
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Vandria"
Vandria - Crunchbase Company Profile & Funding
Organization. Vandria . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Vandria creates mitophagy inducers that …See details»
Vandria - BioAlps
Vandria’s purpose is to research, develop, manufacture and market pharmaceutical products in the life sciences field, in particular the development of products to combat diseases linked to …See details»
Vandria SA - Swiss Biotech
Vandria SA . Swiss Biotech Association. Member. Profile News, events, jobs ... Type of organization. Private company. Year of foundation. 2021. Number of employees in Switzerland. 10-19. Key business. R&D; Core competencies. …See details»
Vandria 2025 Company Profile: Valuation, Funding
Vandria General Information Description. Developer of mitophagy inducers designed to rejuvenate cells to treat age-related and chronic diseases. The …See details»
Vandria SA - Lausanne, Switzerland - bionity.com
Aug 22, 2024 Vandria is at the vanguard of mitochondrial therapeutics. It is developing first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its …See details»
Vandria - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead ... obfuscated +ND Capital, Hevolution: …See details»
Vandria SA Company Profile | Lausanne, VAUD, Switzerland
Find company research, competitor information, contact details & financial data for Vandria SA of Lausanne, VAUD. Get the latest business insights from Dun & Bradstreet.See details»
Vandria - Products, Competitors, Financials, Employees, …
Vandria that focuses on the development of small molecule mitophagy inducers. The company's main offerings include treatments for age-related and chronic diseases, particularly in the …See details»
Vandria Company Profile - Office Locations, Competitors ... - Craft
Vandria has 5 employees at their 1 location and $20.6 m in total funding,. See insights on Vandria including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Vandria - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Vandria SA is a biopharmaceutical spin-off from Amazentis SA and was …See details»
Vandria Announces a CHF 18 Million Fundraising - BioAlps
Mar 21, 2025 Vandria was spun out of Amazentis SA in 2021 with backing by ND Capital to develop first-in-class small molecule mitophagy inducers against a novel target to rejuvenate …See details»
Vandria - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 28, 2025 Vandria has raised a total funding of $30.7M over 2 rounds. Its first funding round was on Dec 14, 2023. Its latest funding round was a Series A round on Aug 23, 2024 for an …See details»
Vandria emerges from stealth with $20.6 million
Dec 14, 2023 Longevity.Technology: Vandria was spun out of Amazentis in 2021 with backing by ND Capital to develop first-in-class small molecule mitophagy inducers against a novel …See details»
Hevolution Foundation and Dolby Family Ventures join Vandria
Aug 21, 2024 About Vandria Vandria is at the vanguard of mitochondrial therapeutics. It is developing first-in-class mitophagy inducers that rejuvenate cells to treat age-related and …See details»
Vandria secures over CHF 14 million | GGBa - Greater Geneva Bern …
Sep 3, 2024 Biotech Vandria has raised an additional CHF 14 million to accelerate the development of innovative treatments for age-related and chronic diseases, bringing its total …See details»
Vandria Gains Momentum with $20.6M Funding to Propel
Dec 18, 2023 Vandria SA, a Swiss biotechnology firm specializing in mitochondrial therapeutics, recently announced a significant milestone in its journey. The company has secured $20.6 …See details»
BioCentury - Vandria: renewing mitochondria to treat CNS, muscle …
Mar 28, 2024 Vandria: renewing mitochondria to treat CNS, muscle and other diseases Swiss biotech Vandria is restoring energy balance in neurons with its first program, soon to enter the …See details»
Vandria Secures $30.7M in Series A to Push Mitophagy
Aug 21, 2024 Vandria SA, a biotech company focused on mitochondrial therapeutics, has completed its Series A funding round, bringing in $30.7 million (CHF 28.3 million).. New …See details»
Vandria raises USD 20.6M and emerges from stealth
Dec 15, 2023 Vandria was spun out of Amazentis SA in 2021 with backing from ND Capital to develop first-in-class small molecule mitophagy inducers against a novel target to rejuvenate …See details»
Novartis receives FDA accelerated approval for Vanrafia® …
5 days ago Ad hoc announcement pursuant to Art. 53 LR. Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS …See details»